(Image: Zen Buddha Silence by Marilyn Barbone.)
December 11, 2016
essay of basant panchami in hindi part of speech test help write a research paper priceline ventolin how to use chewable viagra gold viagra nedir ne bedamn cialis coca cola case study strategic marketing go site https://sugarpinedrivein.com/treatment/alternatives-of-viagra/10/ follow site ghb samen met viagra https://zacharyelementary.org/presentation/you-a-hoe-essay-potna-lyrics/30/ value of money essay does occur protein essay where cuanto cuesta el sildenafil en farmacias guadalajara go https://heystamford.com/writing/pay-to-do-my-assignment/8/ courses list resume https://reprosource.com/hospital/empty-viagra-bottle/72/ does zetia effect kidneys prednisone online buy cheapest generic viagra on the internet effexor xr discounts need to buy a research paper what are sampling techniques in research essay about my country lebanon new york city accutane lawyers viagra free natural no risk walgreens viagra price puede fallar el viagra https://georgehahn.com/playboy/mdicament-viagra-indications-contre/15/ CLINICAL VS. MECHANICAL PREDICTION: A META-ANALYSIS
William Grove, David Zald, Boyd Lebow, Beth Snitz, and Chad Nelson did a meta-analysis (a study of studies) of 136 different studies of human experts vs. simple quant models. Here is a link to the paper by Grove et al. (2000): http://datacolada.org/wp-content/uploads/2014/01/Grove-et-al.-2000.pdf
Here is what Grove et al. discovered about 136 different studies:
- 64 clearly favored the model
- 64 showed approximately the same result between the model and human judgment
- 8 found in favor of human judgment
(NOTE: All eight cases where human judgment prevailed had one thing in common: the humans had more information than the quant models.)
Across all 136 studies that Grove et al. examined, experts were correct in 66.5% of the cases, while the quant models did significantly better with an average hit ratio of 73.2%.
Paul Meehl, one of the founding fathers of the importance of quant models versus human judgments, had this to say:
There is no controversy in social science which shows such a large body of qualitatively diverse studies coming out so uniformly in the same direction as this one… predicting everything from the outcomes of football games to the diagnosis of liver disease. And when you can hardly come up with a half a dozen studies showing even a weak tendency in favor of the clinician, it is time to draw a practical conclusion.
BOOLE MICROCAP FUND
An equal weighted group of micro caps generally far outperforms an equal weighted (or cap-weighted) group of larger stocks over time. See the historical chart here: http://boolefund.com/best-performers-microcap-stocks/
This outperformance increases significantly by focusing on cheap micro caps. Performance can be further boosted by isolating cheap microcap companies that show improving fundamentals. We rank microcap stocks based on these and similar criteria.
There are roughly 10-20 positions in the portfolio. The size of each position is determined by its rank. Typically the largest position is 15-20% (at cost), while the average position is 8-10% (at cost). Positions are held for 3 to 5 years unless a stock approaches intrinsic value sooner or an error has been discovered.
The goal of the Boole Microcap Fund is to outperform the Russell Microcap Index over time, net of fees. The Boole Fund has low fees.
If you are interested in finding out more, please e-mail me or leave a comment.
My e-mail: firstname.lastname@example.org
Disclosures: Past performance is not a guarantee or a reliable indicator of future results. All investments contain risk and may lose value. This material is distributed for informational purposes only. Forecasts, estimates, and certain information contained herein should not be considered as investment advice or a recommendation of any particular security, strategy or investment product. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed. No part of this article may be reproduced in any form, or referred to in any other publication, without express written permission of Boole Capital, LLC.